Openbookopenbook
Equity
ZBH
+0.0 · +0.00%
USD · NYSE

Zimmer Biomet Holdings Inc(ZBH) Stock Analysis | Healthcare

USD --+0.00%
Reward65Moderate
Risk32Moderate
75%Data
Deep Value
Market Cap:19.25Bn
ⓘ
Reward Rating
65
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
32
Moderate
Risk Assessment
1 metric flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ZBH to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for ZBH, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $107.57.

What is Zimmer Biomet Holdings Inc?

, together with its subsidiaries, operates as a medical technology company worldwide.

ZBH · Verdict

Solid reward · moderate risk

ZBH stands out on valuation and volatility, but watch the balance sheet signal.

Based on 88% data coverage

ZBH · Verdict

What’s working & what to watch

Strengths 4

  • Valuation86/100

    P/E 11.7× · PEG 0.67

  • Volatility80/100

    Top decile vs peers

  • Cash flow77/100

    18% free-cash-flow margin

  • Profitability72/100

    9% net margin · 6% ROE

Watchouts 1

  • Balance sheet42/100

    Interest covered 3.8×

Model-based scoring. For information only — not financial advice.

What is Zimmer Biomet Holdings Inc?

, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 19.25B, and a P/E ratio of 24.5x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (65)

The scoring profile indicates moderate reward potential, with valuation and profitability as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

STELarge Cap / 22.7B market cap
STERIS plc
Compare
SONVFLarge Cap / 15.8B market cap
Sonova Holding AG
Compare
SNNUFLarge Cap / 14.9B market cap
Smith & Nephew plc
Compare
Company Information
SectorHealthcare
IndustryMedical Devices
Market Cap19.25B
P/E Ratio24.4927
Dividend Yield0.97%
Beta0.462
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.
11 disclosures without share count
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.